A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.
Assessments of MET copy number gain are not predictive of benefit from TKI therapy in EGFR-mutant NSCLC, according to researchers.
Illumina’s TruSight Oncology 500 next-generation sequencing assay has been assigned a breakthrough device status by the FDA.
A single definition of TMB as a predictor of survival benefit from immune checkpoint inhibitors across cancer types is not feasible, according to authors.
